LU90392I2 - Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone - Google Patents
Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasoneInfo
- Publication number
- LU90392I2 LU90392I2 LU90392C LU90392C LU90392I2 LU 90392 I2 LU90392 I2 LU 90392I2 LU 90392 C LU90392 C LU 90392C LU 90392 C LU90392 C LU 90392C LU 90392 I2 LU90392 I2 LU 90392I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- salmeterol
- acceptable salt
- fluticasone propionate
- xinafoate
- naphthoate
- Prior art date
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000289 fluticasone propionate Drugs 0.000 title abstract 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title abstract 2
- 229960004017 salmeterol Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 title 1
- 229950000339 xinafoate Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898920392A GB8920392D0 (en) | 1989-09-08 | 1989-09-08 | Medicaments |
| GB898923644A GB8923644D0 (en) | 1989-10-20 | 1989-10-20 | Medicaments |
| SG166294A SG166294G (en) | 1989-09-08 | 1994-11-18 | Inhalation medicaments for treating respiratory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU90392I2 true LU90392I2 (fr) | 1999-06-28 |
Family
ID=27264677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU90392C LU90392I2 (fr) | 1989-09-08 | 1999-04-26 | Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0416951B1 (enExample) |
| JP (1) | JP3042867B2 (enExample) |
| AT (1) | ATE99941T1 (enExample) |
| BE (1) | BE1003053A3 (enExample) |
| CA (1) | CA2024916C (enExample) |
| CH (1) | CH680983C9 (enExample) |
| DE (2) | DE69005951T2 (enExample) |
| DK (1) | DK0416951T3 (enExample) |
| ES (1) | ES2062392T3 (enExample) |
| FR (1) | FR2651677B1 (enExample) |
| HK (1) | HK18695A (enExample) |
| HU (1) | HU211272A9 (enExample) |
| IE (1) | IE65535B1 (enExample) |
| IL (1) | IL95590A (enExample) |
| IT (1) | IT1241996B (enExample) |
| LU (1) | LU90392I2 (enExample) |
| NL (1) | NL990012I2 (enExample) |
| NZ (1) | NZ235221A (enExample) |
| PH (1) | PH27594A (enExample) |
| SG (1) | SG166294G (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| HU0004452D0 (enExample) * | 1991-12-18 | 2001-01-29 | Astra Ab | |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| AU756852B2 (en) | 1998-11-13 | 2003-01-23 | Jagotec Ag | Dry powder for inhalation |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| GB2354007B (en) | 1999-09-11 | 2003-10-22 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| ATE291898T1 (de) * | 1999-12-24 | 2005-04-15 | Glaxo Group Ltd | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| AU2001275760B2 (en) | 2000-08-05 | 2005-03-17 | Glaxo Group Limited | 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1370521B1 (en) | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
| HU228508B1 (en) | 2001-09-14 | 2013-03-28 | Glaxo Group Ltd | Phenethanolamine derivatives and pharmaceutical composition containing them |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| WO2003066033A1 (en) † | 2002-02-04 | 2003-08-14 | Glaxo Group Limited | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| EP1757281A3 (en) * | 2002-02-04 | 2009-07-15 | Glaxo Group Limited | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| AU2003221482A1 (en) * | 2002-03-04 | 2003-09-16 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Novel cinnamate salts, method for production and use thereof as medicaments |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| RS51707B (sr) | 2002-12-12 | 2011-10-31 | Nycomed Gmbh. | Kombinacija leka sastavljena od r, r - formoterola i ciklezonida |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| SE527069C2 (sv) | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
| CA2534934A1 (en) | 2003-08-06 | 2005-02-17 | Galephar M/F | Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| AP2006003734A0 (en) * | 2004-03-12 | 2006-10-31 | Cipla Ltd | Inhalation formulation |
| KR101214823B1 (ko) | 2004-07-16 | 2012-12-24 | 알미랄, 에스.에이. | 분말 약제의 투약을 위한 흡입기 및 이 흡입기와 함께사용하기 위한 분말 카트리지 시스템 |
| UA95506C2 (uk) | 2006-12-22 | 2011-08-10 | Альміраль, С.А. | Інгаляційний пристрій для медикаментів у порошковій формі |
| CN101744792B (zh) * | 2008-12-17 | 2013-04-17 | 张凯 | 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| DK2435023T3 (en) | 2009-05-29 | 2016-10-24 | Pearl Therapeutics Inc | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2-adrenergic receptor agonists and associated methods and systems |
| ES2712988T5 (es) | 2013-03-15 | 2022-10-21 | Pearl Therapeutics Inc | Métodos y sistemas para acondicionamiento de materiales cristalinos en partículas |
| CN105324107A (zh) * | 2013-04-29 | 2016-02-10 | 赛诺菲股份有限公司 | 可吸入药用组合物和含有该药用组合物的吸入器装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2107715B (en) * | 1981-10-19 | 1985-11-13 | Glaxo Group Ltd | Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| FR2588474B1 (fr) * | 1985-10-16 | 1987-11-27 | Cird | Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste |
-
1990
- 1990-09-05 IL IL9559090A patent/IL95590A/en not_active IP Right Cessation
- 1990-09-07 NZ NZ235221A patent/NZ235221A/en unknown
- 1990-09-07 JP JP2235997A patent/JP3042867B2/ja not_active Expired - Lifetime
- 1990-09-07 PH PH41153A patent/PH27594A/en unknown
- 1990-09-07 DE DE69005951T patent/DE69005951T2/de not_active Expired - Lifetime
- 1990-09-07 ES ES90309846T patent/ES2062392T3/es not_active Expired - Lifetime
- 1990-09-07 DE DE1990605951 patent/DE19975040I2/de active Active
- 1990-09-07 EP EP90309846A patent/EP0416951B1/en not_active Expired - Lifetime
- 1990-09-07 IE IE325690A patent/IE65535B1/en not_active IP Right Cessation
- 1990-09-07 FR FR909011142A patent/FR2651677B1/fr not_active Expired - Lifetime
- 1990-09-07 IT IT48260A patent/IT1241996B/it active Protection Beyond IP Right Term
- 1990-09-07 AT AT90309846T patent/ATE99941T1/de active
- 1990-09-07 CH CH2906/90A patent/CH680983C9/de not_active IP Right Cessation
- 1990-09-07 CA CA002024916A patent/CA2024916C/en not_active Expired - Lifetime
- 1990-09-07 DK DK90309846.5T patent/DK0416951T3/da active
- 1990-09-07 BE BE9000862A patent/BE1003053A3/fr not_active IP Right Cessation
-
1994
- 1994-11-18 SG SG166294A patent/SG166294G/en unknown
-
1995
- 1995-02-09 HK HK18695A patent/HK18695A/xx not_active IP Right Cessation
- 1995-06-02 HU HU95P/P00150P patent/HU211272A9/hu unknown
-
1999
- 1999-04-14 NL NL990012C patent/NL990012I2/nl unknown
- 1999-04-26 LU LU90392C patent/LU90392I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0416951T3 (da) | 1994-02-14 |
| CA2024916A1 (en) | 1991-03-09 |
| EP0416951B1 (en) | 1994-01-12 |
| IL95590A (en) | 1996-06-18 |
| IT1241996B (it) | 1994-02-02 |
| DE69005951D1 (de) | 1994-02-24 |
| PH27594A (en) | 1993-08-31 |
| CH680983C9 (enExample) | 2008-08-15 |
| FR2651677B1 (fr) | 1993-08-06 |
| NZ235221A (en) | 1992-11-25 |
| IE65535B1 (en) | 1995-11-01 |
| CH680983C1 (enExample) | 2008-06-25 |
| IT9048260A0 (it) | 1990-09-07 |
| IE903256A1 (en) | 1991-03-13 |
| HK18695A (en) | 1995-02-17 |
| NL990012I1 (nl) | 1999-07-01 |
| ES2062392T3 (es) | 1994-12-16 |
| IT9048260A1 (it) | 1992-03-07 |
| ATE99941T1 (de) | 1994-01-15 |
| NL990012I2 (nl) | 1999-09-01 |
| SG166294G (en) | 1995-06-16 |
| JPH03167120A (ja) | 1991-07-19 |
| DE69005951T2 (de) | 1994-05-26 |
| EP0416951A1 (en) | 1991-03-13 |
| FR2651677A1 (fr) | 1991-03-15 |
| HU211272A9 (en) | 1995-11-28 |
| DE19975040I2 (de) | 2006-07-13 |
| CH680983A5 (enExample) | 1992-12-31 |
| IL95590A0 (en) | 1991-09-16 |
| BE1003053A3 (fr) | 1991-11-05 |
| JP3042867B2 (ja) | 2000-05-22 |
| CA2024916C (en) | 2002-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU90392I2 (fr) | Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone | |
| CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
| CA2123909A1 (en) | New combination of formoterol and budesonide | |
| DE69002718D1 (de) | Medikamente. | |
| BR0008699A (pt) | Combinações de formoterol e furoato demometasona para asma | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| BG102689A (bg) | Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения | |
| ZA876731B (en) | Therapeutic agents | |
| GB9523442D0 (en) | Calcitonin salmon analogues,their preparation,medicinal use and use as analytical agents | |
| CA2038744A1 (en) | Pharmaceutical composition containing slightly water-soluble drug | |
| HUP0202525A2 (hu) | Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit | |
| HUP0002533A2 (hu) | Asztmaellenes gyógyszerhatóanyagok új kombinációja | |
| MY111155A (en) | Medicaments |